NOT KNOWN FACTS ABOUT RAVOXERTINIB

Proteolysis-concentrating on chimeras (PROTACs) and molecular glue degraders (MGDs) are probably the most maturely developed TPD approaches. Within this assessment, we target both of those preclinical experiments and clinical trials to provide a comprehensive summary of the protection and medical efficiency of PROTACs and MGDs in hematologic malign